Cortexyme is a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what we believe to be a key underlying cause of Alzheimer’s and other degenerative diseases. Cortexyme is targeting a specific pathogen found in the brain of Alzheimer’s patients that causes neurodegeneration and other pathology in animal models. Cortexyme’s lead small molecule, COR388, has advanced through preclinical and Phase Ib testing and is currently the subject of a Phase 2/3 GAIN clinical trial in mild to moderate Alzheimer’s disease patients.